CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6843-6850

  Chung, Yeonseok ^a   Kim, Byung Seok ^a   Kim, Yeon Jeong ^a   Ko, Hyun Jeong ^a   Ko, Sung Youl ^a   Kim, Dong Hyeon ^a   Kang, Chang Yuil ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; DENDRITIC CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MEMORY T LYMPHOCYTE; METASTASIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD1; B-LYMPHOCYTES; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; GALACTOSYLCERAMIDES; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33746167864     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0889     Document Type: Article

References (46)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
3. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001;106:271-4.
4. Schultze JL, Grabbe S, von Bergwelt-Baildon MS. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 2004;25:659-64.
5. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-25.
6. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
7. Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR. B cells directly tolerize CD8(+) T cells. J Exp Med 1998;188:1977-83.
8. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 1992;175:131-8.
9. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992;258:1156-9.
10. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
11. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004;103:2046-54.
12. Kondo E, Topp MS, Kiem HP, et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002;169:2164-71.
13. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004;172:1501-7.
14. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900.
15. Park SH, Bendelac A. CD1-restricted T-cell responses and microbial infection. Nature 2000;406:788-92.
16. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
17. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-6.
18. Sharif S, Arreaza GA, Zucker P, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001;7:1057-62.
19. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999;190:1215-26.
20. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000;1:521-5.
21. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003;171:5140-7.
22. + T cells in vivo. J Immunol 2003;170:2540-8.
23. Crowe NY, Coquet JM, Berzins SP, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005;202:1279-88.
24. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-33.
25. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat Immunol 2002;3:867-74.
26. + dendritic cells mediate cross-tolerance toward intestinal antigens. Blood 2005;106:201-6.
27. Chung Y, Chang WS, Kim S, Kang CY. NKT cell ligand α- galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol 2004;34:2471-9.
28. Chung Y, Ko SY, Ko HJ, Kang CY. Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens. Eur J Immunol 2005;35:1381-90.
29. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004;111:86-95.
30. Zhou D, Mattner J, Cantu C, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-9.
31. + T cell cross-priming via transfer of proteasome substrates. Science 2004;304:1318-21.
32. Nagata Y, Furugen R, Hiasa A, et al. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997;159:1336-43.
33. Liu K, Idoyaga J, Charalambous A, et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 2005;202:1507-16.
34. Bezbradica JS, Stanic AK, Matsuki N, et al. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol 2005;174:4696-705.
35. +) T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002;99:1259-66.
36. Hammond KJ, Pellicci DG, Poulton LD, et al. CD1d-restricted NKT cells: an interstrain comparison. J Immunol 2001;167:1164-73.
37. Hameg A, Apostolou I, Leite-De-Moraes M, et al. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the α-galactosylceramide antigen. J Immunol 2000;165:4917-26.
38. Berzins SP, Smyth MJ, Godfrey DI. Working with NKT cells-pitfalls and practicalities. Curr Opin Immunol 2005;17:448-54.
39. Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med 2003;197:1051-7.
40. Chung Y, Kim DH, Lee SH, Kang CY. Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance. Immunology 2004;111:19-26.
41. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. α- Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2006;175:3309-17.
42. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004;21:401-13.
43. Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004;4:181-98.
44. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol 2002;13:52-6.
45. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003;17:1068-77.
46. Fais F, Morabito F, Stelitano C, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates α-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004;109:402-11.